RenovoRx's TAMP Platform Shows Promising PK Data in Phase 3 Pancreatic Cancer Trial at ASCO
RNXT sits 24% above its 52-week low of $0.701.
Summary
RenovoRx announced promising pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial, presented at the ASCO Annual Meeting. The data indicates its TAMP platform for targeted intra-arterial gemcitabine delivery can increase local drug potency and reduce systemic side effects for pancreatic cancer. This positive clinical development builds on the company's recent progress in the TIGeR-PaC trial, including surpassing 100 randomized patients, and strong Q1 2026 financial results. The findings suggest a potential for improved efficacy and patient tolerability in a challenging cancer, which is highly significant for the company's lead investigational product. Investors will be watching for further details from the ASCO presentation and ongoing trial results.
At the time of this announcement, RNXT was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.